Biomarkers for Selection of Extended Endocrine Therapy in HR+ Breast Cancer
Experts discuss biomarkers used to determine if a patient with HR+ breast cancer will benefit from extended endocrine therapy.
EP: 1.The Evolution of Early-Stage HR+ Breast Cancer Management
EP: 2.Measuring Ki-67 Levels to Inform HR+ Breast Cancer Treatment
EP: 3.Updated Guidelines for the Management of HR+ Breast Cancer
EP: 4.Recurrence Patterns in Early-Stage HR+ Breast Cancer
EP: 5.Tools to Guide Treatment Decision-Making in HR+ Breast Cancer
EP: 6.Ordering Additional Multigene Assays for Patients with HR+ Breast Cancer
EP: 7.Data on Extended Adjuvant Endocrine Therapy in HR+ Breast Cancer
Now Viewing
EP: 8.Biomarkers for Selection of Extended Endocrine Therapy in HR+ Breast Cancer
EP: 9.Clinical and Practical Implications of the Breast Cancer Index
EP: 10.Future Directions in HR+ Breast Cancer Management
Related Videos
Related Content
